(19) World Intellectual Property Organization International Bureau



(43) International Publication Date 11 December 2003 (11.12.2003)

PCT

(10) International Publication Number WO 03/102019 A2

(51) International Patent Classification7:

C07K

- (21) International Application Number: PCT/US03/17638
- (22) International Filing Date: 4 June 2003 (04.06.2003)
- (25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data: 10/161,996

4 June 2002 (04.06.2002) US

- (71) Applicant (for all designated States except US): ISIS PHARMACEUTICALS, INC. [US/US]; 2292 Faraday Avenue, Carlsbad, CA 92008 (US).
- (72) Inventors; and
- (75) Inventors/Applicants (for US only): FRIER, Susan, M. [US/US]; 2946 Renault Street, San Diego, CA 92122 (US). BAKER, Brenda, F. [US/US]; 2147 Avenida Toronja, Carlsbad, CA 92009 (US). DOBIE, Kenneth, W. [GB/US]; 703 Stratford Ct., #4, Del Mar, CA 92014 (US).
- (74) Agent: COZEN O'CONNOR P.C.; 1900 Market Street, Philadelphia, PA 19103 (US).

- (81) Designated States (national): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW.
- (84) Designated States (regional): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG).

Published:

 without international search report and to be republished upon receipt of that report

For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: ANTISENSE MODULATION OF STEROL REGULATORY ELEMENT-BINDING PROTEIN-1 EXPRESSION

(57) Abstract: Antisense compounds, compositions and methods are provided for modulating the expression of sterol regulatory element-binding protein-1. The compositions comprise antisense compounds, particularly antisense oligonucleotides, targeted to nucleic acides encoding sterol regulatory element-binding protein-1. Methods of using these compounds for modulation of sterol regulatory element-binding protein-1 expression and for treatment of diseases associated with expression of sterol regulatory element-binding protein-1 are provided.